|Bid||281.70 x 1100|
|Ask||0.00 x 1000|
|Day's Range||281.78 - 285.41|
|52 Week Range||225.65 - 355.88|
|Beta (3Y Monthly)||1.01|
|PE Ratio (TTM)||22.08|
|Earnings Date||Jul 31, 2019|
|Forward Dividend & Yield||2.20 (0.77%)|
|1y Target Est||319.38|
Congress will be voting Wednesday on a repeal of what is known as the “Cadillac Tax," which is a provision of the Affordable Care Act that would place a 40% tax on employer-sponsored health care plans that provide excess benefits. Yahoo Finance's Anjalee Khemlani breaks down what the provision does and what could come from the vote.
Yahoo Finance's Brian Sozzi, Alexis Christoforous, and Anjalee Khemlani break down what's driving the health care sector higher.
The Treasury Department and IRS issued a notice Wednesday that will help high deductible plan enrollees qualify for more preventative care benefits, which expands the uses for Health Savings Accounts.
Announces Additional Participants in Bundled Payment Models for Spinal Fusion and Total Joint Replacement Surgeries
The Zacks Analyst Blog Highlights: Cisco, Home Depot, Merck, Humana and Public Service Enterprise
Humana's stock jumped at the news that the White House intends to rework how the nation deals with kidney health.
Humana (HUM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
After many regulatory disturbances and overhang of the drug rebate ban proposal, a repeal of it is a breather for health insurers.
On Thursday, the Trump administration announced the withdrawal of the proposal to abolish rebates paid to pharmacy benefit managers by drugmakers.
The Trump administration announced Thursday that it's deciding to withdraw its proposal to eliminate rebates from government drug plans.
Shares of dialysis company DaVita are up a day after President Trump issued an executive order that could upend kidney care in the U.S., and analysts say health-insurance companies could win, too.
AM Best has revised the outlooks to positive from stable and affirmed the Financial Strength Rating (FSR) of A- (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a-” for the majority of the health insurance subsidiaries of Humana Inc. (Humana) (headquartered in Louisville, KY) [NYSE: HUM]. Concurrently, AM Best has revised the outlook to positive from stable and affirmed the Long-Term ICR of “bbb-”, as well as the existing Long-Term Issue Credit Ratings of Humana. AM Best also has affirmed the Short-Term Issue Credit Rating of Humana.
Today we are going to look at Humana Inc. (NYSE:HUM) to see whether it might be an attractive investment prospect...
Humana Inc. (HUM) will release its financial results for the second quarter 2019 (2Q19) on Wednesday, July 31, 2019 at 6:30 a.m. eastern time. The company will host a conference call at 9:00 a.m. eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2019. A webcast of the 2Q19 earnings call may also be accessed via Humana’s Investor Relations page at www.humana.com.
Growth in Walgreens Boots Alliance Inc.’s U.S. retail pharmacy business helped drive an increase in sales in the third quarter, but the drugstore chain still faces some significant challenges.
Health insurance was a source of contention in the first Democratic debate, with Sen. Elizabeth Warren leaving no space between her and her most formidable liberal rival, Sen. Bernie Sanders, by not seeing a role for private insurers.
Ascension Saint Thomas is seeking approval to build a new rehab facility on its Midtown campus to care for a projected increase in neuroscience, cardiac and joint-replacement patients.
Company officials said it is hiring for all three of its offices: Austin, Scottsdale and San Francisco. The company was founded in Arizona but relocated its headquarters to Texas in 2016.